Keeping up with the growing body of case law is a must for IP lawyers. Federal Circuit decisions can impact your client’s IP portfolio strategy on many levels and in significant or subtle ways. Some decisions are of particular importance and well worth a closer look.
The editorial team of Finnegan’s Last Month at the Federal Circuit newsletter is pleased to present a quarterly series of webinars that examine significant cases and offer expert commentary on their implications and potential impact. Please join our panelists as they discuss:
Association for Molecular Pathology v. USPTO
• Considers question of patentability under Section 101 after In re Bilski
• Finds that claims directed to isolated DNA molecules and to a screening method are patent-eligible under Section 101, while claims directed to analyzing and comparing nucleotide sequences are not patent-eligible
Classen Immunotherapies, Inc. v. Biogen Idec
• Considers question of patentability under Section 101 after In re Bilski and provides policy discussion of Section 101
• Finds that claims directed to a single step of reviewing the effects of known immunization schedules are not patent eligible under Section 101, while claims that further include an act of immunization in accordance with a lower-risk schedule are patent-eligible
This webinar is the third in our 2011 “Last Quarter at the Federal Circuit Webinar Series.” We hope you are able to attend.
Speakers:
Shana K. Cyr, Ph.D.
Date:
Tuesday, October 25, 2011
Time:
1:00 - 2:00 p.m. EDT
